These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 18669894)

  • 1. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement.
    Caminschi I; Proietto AI; Ahmet F; Kitsoulis S; Shin Teh J; Lo JC; Rizzitelli A; Wu L; Vremec D; van Dommelen SL; Campbell IK; Maraskovsky E; Braley H; Davey GM; Mottram P; van de Velde N; Jensen K; Lew AM; Wright MD; Heath WR; Shortman K; Lahoud MH
    Blood; 2008 Oct; 112(8):3264-73. PubMed ID: 18669894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141
    Pearson FE; Tullett KM; Leal-Rojas IM; Haigh OL; Masterman KA; Walpole C; Bridgeman JS; McLaren JE; Ladell K; Miners K; Llewellyn-Lacey S; Price DA; Tunger A; Schmitz M; Miles JJ; Lahoud MH; Radford KJ
    Clin Transl Immunology; 2020; 9(6):e1141. PubMed ID: 32547743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic Transformation of Dendritic Cells and Their Precursors Leads to Rapid Cancer Development in Mice.
    Böttcher JP; Zelenay S; Rogers NC; Helft J; Schraml BU; Reis e Sousa C
    J Immunol; 2015 Nov; 195(10):5066-76. PubMed ID: 26459350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype.
    Lahoud MH; Ahmet F; Kitsoulis S; Wan SS; Vremec D; Lee CN; Phipson B; Shi W; Smyth GK; Lew AM; Kato Y; Mueller SN; Davey GM; Heath WR; Shortman K; Caminschi I
    J Immunol; 2011 Jul; 187(2):842-50. PubMed ID: 21677141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity.
    Sancho D; Joffre OP; Keller AM; Rogers NC; Martínez D; Hernanz-Falcón P; Rosewell I; Reis e Sousa C
    Nature; 2009 Apr; 458(7240):899-903. PubMed ID: 19219027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells.
    Schreibelt G; Klinkenberg LJ; Cruz LJ; Tacken PJ; Tel J; Kreutz M; Adema GJ; Brown GD; Figdor CG; de Vries IJ
    Blood; 2012 Mar; 119(10):2284-92. PubMed ID: 22234694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments.
    Zhang JG; Czabotar PE; Policheni AN; Caminschi I; Wan SS; Kitsoulis S; Tullett KM; Robin AY; Brammananth R; van Delft MF; Lu J; O'Reilly LA; Josefsson EC; Kile BT; Chin WJ; Mintern JD; Olshina MA; Wong W; Baum J; Wright MD; Huang DC; Mohandas N; Coppel RL; Colman PM; Nicola NA; Shortman K; Lahoud MH
    Immunity; 2012 Apr; 36(4):646-57. PubMed ID: 22483802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates.
    Li J; Ahmet F; Sullivan LC; Brooks AG; Kent SJ; De Rose R; Salazar AM; Reis e Sousa C; Shortman K; Lahoud MH; Heath WR; Caminschi I
    Eur J Immunol; 2015 Mar; 45(3):854-64. PubMed ID: 25487143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy.
    Zeng B; Middelberg AP; Gemiarto A; MacDonald K; Baxter AG; Talekar M; Moi D; Tullett KM; Caminschi I; Lahoud MH; Mazzieri R; Dolcetti R; Thomas R
    J Clin Invest; 2018 May; 128(5):1971-1984. PubMed ID: 29485973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boosting antibody responses by targeting antigens to dendritic cells.
    Caminschi I; Shortman K
    Trends Immunol; 2012 Feb; 33(2):71-7. PubMed ID: 22153931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells.
    Poulin LF; Salio M; Griessinger E; Anjos-Afonso F; Craciun L; Chen JL; Keller AM; Joffre O; Zelenay S; Nye E; Le Moine A; Faure F; Donckier V; Sancho D; Cerundolo V; Bonnet D; Reis e Sousa C
    J Exp Med; 2010 Jun; 207(6):1261-71. PubMed ID: 20479117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas.
    Picco G; Beatson R; Taylor-Papadimitriou J; Burchell JM
    Eur J Immunol; 2014 Jul; 44(7):1947-55. PubMed ID: 24648154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy.
    Yan Z; Wu Y; Du J; Li G; Wang S; Cao W; Zhou X; Wu C; Zhang D; Jing X; Li Y; Wang H; Gao Y; Qi Y
    Oncotarget; 2016 Jun; 7(26):40437-40450. PubMed ID: 27250027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice.
    Zelenay S; Keller AM; Whitney PG; Schraml BU; Deddouche S; Rogers NC; Schulz O; Sancho D; Reis e Sousa C
    J Clin Invest; 2012 May; 122(5):1615-27. PubMed ID: 22505458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens.
    Jongbloed SL; Kassianos AJ; McDonald KJ; Clark GJ; Ju X; Angel CE; Chen CJ; Dunbar PR; Wadley RB; Jeet V; Vulink AJ; Hart DN; Radford KJ
    J Exp Med; 2010 Jun; 207(6):1247-60. PubMed ID: 20479116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of B cell responses to Clec9A-targeted antigen.
    Park HY; Light A; Lahoud MH; Caminschi I; Tarlinton DM; Shortman K
    J Immunol; 2013 Nov; 191(10):4919-25. PubMed ID: 24123689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells.
    Bachem A; Güttler S; Hartung E; Ebstein F; Schaefer M; Tannert A; Salama A; Movassaghi K; Opitz C; Mages HW; Henn V; Kloetzel PM; Gurka S; Kroczek RA
    J Exp Med; 2010 Jun; 207(6):1273-81. PubMed ID: 20479115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues.
    Poulin LF; Reyal Y; Uronen-Hansson H; Schraml BU; Sancho D; Murphy KM; Håkansson UK; Moita LF; Agace WW; Bonnet D; Reis e Sousa C
    Blood; 2012 Jun; 119(25):6052-62. PubMed ID: 22442345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harnessing Human Cross-Presenting CLEC9A(+)XCR1(+) Dendritic Cells for Immunotherapy.
    Tullett KM; Lahoud MH; Radford KJ
    Front Immunol; 2014; 5():239. PubMed ID: 24904587
    [No Abstract]   [Full Text] [Related]  

  • 20. Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1.
    Hartung E; Becker M; Bachem A; Reeg N; Jäkel A; Hutloff A; Weber H; Weise C; Giesecke C; Henn V; Gurka S; Anastassiadis K; Mages HW; Kroczek RA
    J Immunol; 2015 Feb; 194(3):1069-79. PubMed ID: 25520399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.